OpGen Inc (NASDAQ:OPGN) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Wednesday.

According to Zacks, “OpGen, Inc. is a microbial genetics analysis company. The Company offers optical mapping services for analysis of microbial, yeast and fungal genomic architecture. OpGen, Inc. headquartered in Gaithersburg, Maryland. “

Separately, Rodman & Renshaw set a $3.30 price target on OpGen and gave the company a “buy” rating in a report on Wednesday, August 10th.

OpGen (NASDAQ:OPGN) opened at 1.61 on Wednesday. OpGen has a one year low of $1.02 and a one year high of $4.65. The stock’s market cap is $34.88 million. The stock’s 50 day moving average price is $1.66 and its 200 day moving average price is $1.61.

OpGen (NASDAQ:OPGN) last announced its earnings results on Tuesday, August 9th. The company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by $0.09. Equities analysts predict that OpGen will post ($1.17) earnings per share for the current fiscal year.

About OpGen

OpGen, Inc (OpGen) is a developer of precision medicine tools. The Company uses molecular testing and bioinformatics to help guide antibiotic therapy and to assist healthcare providers to combat multi-drug resistant infections (MDROs). The Company’s lead products include the QuickFISH and PNAFISH products, which are in vitro diagnostic kits for the diagnosis and prevention of infectious diseases; the Acuitas MDRO Gene Test, which is a lab-based test that provides a profile of MDRO resistant genes from patients screened for colonization or infection, and the Acuitas Lighthouse, which is used to aid in the interpretation of MDRO diagnostic test results.

5 Day Chart for NASDAQ:OPGN

Receive News & Stock Ratings for OpGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen Inc and related stocks with our FREE daily email newsletter.